Combining talazoparib with low dose radiotherapy for extensive-stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I clinical trial evaluates the safety and maximum tolerated dose of talazoparib when combined with low dose thoracic radiotherapy in patients with extensive-stage small cell lung cancer who have stable disease after standard chemotherapy. Patients will begin taking talazoparib orally on day 1 and will receive low dose radiotherapy starting on day 6-9, continuing for 10 fractions over two weeks. The study aims to monitor clinical outcomes such as locoregional recurrence, progression-free survival, and overall survival, as well as assess acute and chronic toxicities over a year.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological documented diagnosis of SCLC confirmed by a UHN pathologist.
* Documented extensive disease
* Completion of induction chemotherapy, 4-6 cycles of a platinum agent and etoposide.
* No disease progression (i.e.SD or better response by RECIST 1.1) at the completion of chemotherapy.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnosfsky Performance Score (KPS) ≥50; see Appendix B).
* Adequate organ and marrow function,
* Postmenopausal or evidence of non-childbearing status for women of childbearing potential negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.

Exclusion Criteria:

* Untreated brain metastases.
* Previous radiotherapy to thorax (prior breast RT is permitted).
* Patients receiving any systemic chemotherapy, radiotherapy or immunotherapy (except for standard of care treatments or palliative reasons) within 3 weeks prior to study treatment.
* Exposure to an investigational product within 30 days or 5 half-lives (whichever is longer) prior to start of the current study drug.
* Any previous treatment with PARP inhibitor, including talazoparib.
* Concomitant use of strong P-gp inhibitors
* Concomitant use of other known P-gp inhibitors, P-gp inducers, or BCRP inhibitors
* Persistent toxicities (\>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia.
* Patients with myelodysplastic syndrome/acute leukaemia or with features suggestive thereof.
* Major surgery within 2 weeks of study treatment initiation and patients must have recovered from any effects of any major surgery.
* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active/uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent
* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
* Immunocompromised patients,
* Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
* Whole blood transfusions in the last 120 days prior to entry to the study
* Other malignancy within the last 5 years
* Patients with spinal cord compression

Where it's running

• Princess Margaret Cancer Center, University Health Network
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Benjamin Lok, MD — Princess Margaret Cancer Center
• Study coordinator: Benjamin Lok, MD
• Email: Benjamin.Lok@rmp.uhn.ca
• Phone: 416-946-4501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Observational study on characteristics and outcomes of patients with surgically removed lung cancers

  This study looks at patients in China who have had lung cancer surgery to see how their treatment and outcomes vary and what factors might affect their survival.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06255197

• Dose-reduced chemotherapy for lung cancer patients with health issues

  This study is testing if a lower dose of chemotherapy can help lung cancer patients with other health issues feel better and manage their treatment safely.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05800587

• Combining Trilaciclib with Lurbinectedin for Small-cell Lung Cancer

  This study is testing if adding Trilaciclib can help reduce side effects from Lurbinectedin in patients with advanced small-cell lung cancer who have already tried other treatments.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Lebanon, New Hampshire and 1 other locations · NCT05578326

• Stereotactic radiosurgery for lung cancer that has spread to the brain

  This study is testing if a targeted radiation treatment can help people with small cell lung cancer that has spread to their brain feel better and improve their outcomes.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05419076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.